Despite the large number of works on the synthesis of polylactide-co-glycolide (PLGA) nanoparticles (NP) loaded with antituberculosis drugs, the data on the influence of various factors on the final characteristics of the complexes are quite contradictory. In the present study, a comprehensive analysis of the effect of multiple factors, including the molecular weight of PLGA, on the size and stability of nanoparticles, as well as the loading efficiency and release of the antituberculosis drug rifampicin (RIF), was carried out. Emulsification was carried out using different surfactants (polyvinyl alcohol, Tween 80 and Pluronic F127), different aqueous-to-organic phase ratios, and different solvents (dichloromethane, dimethyl sulfoxide, ethyl acetate). In this research, the PLGA nanoemulsion formation process was accompanied by ultrasonic dispersion, at different frequencies and durations of homogenization. The use of the central composite design method made it possible to select optimal conditions for the preparation of PLGA-RIF NPs (particle size 223 ± 2 nm, loading efficiency 67 ± 1%, nanoparticles yield 47 ± 2%). The release of rifampicin from PLGA NPs was studied for the first time using the flow cell method and vertical diffusion method on Franz cells at different pH levels, simulating the gastrointestinal tract. For the purpose of the possible inhalation administration of rifampicin immobilized in PLGA NPs, their mucoadhesion to mucin was studied, and a high degree of adhesion of polymeric nanoparticles to the mucosa was shown (more than 40% within 4 h). In the example of strain H37Rv in vitro, the sensitivity of Mycobacterium tuberculosis to PLGA-RIF NPs was proven by the complete inhibition of their growth.
The global problem of tuberculosis (ТВ) requires advanced drug delivery systems that improve treatment efficacy. In this study, polylactic acid (PLA)-based drug carriers were developed for the controlled delivery of the first-line anti-TB drugs isoniazid (INH) and rifampicin (RIF). The main objective of this study is to improve PLA-based NP formulations through optimization to achieve maximum drug content coupled with enhanced stability to improve treatment outcomes. PLA-RIF-INH nanoparticles (NPs) were prepared by double emulsion method using ultrasonic homogenizer, using different surfactants (polyvinyl alcohol, Tween-80 and Pluronic F-127) and with different organic solutions (dichloromethane, dimethyl sulfoxide and ethyl acetate) at different phase ratios. The produced NPs had an average size of 197±8 nm with a polydispersity index of 0.287±0.048 and contained 23±2 % INH and 20±8 % RIF for a NPs yield of 65±2 %. The release of drugs from PLA NPs was investigated using the flow cell method and the vertical diffusion method at different pH values simulating gastrointestinal conditions. It was shown that PLA-RIF-INH NPs have pronounced antimycobacterial activity against Mycobacterium tuberculosis H37Rv and isoniazid-resistant strain, which confirms the prospect of their use in tuberculosis therapy.
This study involved the synthesis of bovine serum albumin (BSA) nanoparticles immobilized with the antituberculosis drugs isoniazid (INH) and rifampicin (RIF) by the desolvation method. The primary objective was to explore the impact of varying concentrations of albumin, urea, cysteine, rifampicin, and isoniazid on the average size of nanoparticles, polydispersity, and the encapsulation efficiency of drugs. The study's outcomes affirm that alterations in the concentrations of these components influence nanoparticles’ parameters, highlighting their key role in optimizing the encapsulation process and enhancing the efficacy of tuberculosis drug delivery. The nanoparticles obtaned as a result of optimization demonstrated an optimal size of 231.2±1.2 nm with a polydispersity of 0.061±0.08. Encapsulation efficiency was 89% for rifampicin and 38.5% for isoniazid. The investigation of drug release kinetics from the polymer matrix revealed a gradual release pattern. Evaluation of the obtained nanoparticles by Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC) confirmed the successful incorporation of drugs into the polymer matrix. These findings highlight the potential of BSA nanoparticles as effective carriers for tuberculosis treatment, with implications for refining drug delivery strategies.
The aim of this study was to synthesize and optimize polylactide-co-glycolide (PLGA) nanoparticles loaded with rifampicin (RIF), with a given size and high loading rate, using the central composite design (CCD) method. CCD was used to investigate the influence of independent factors such as PLGA:RIF ratio, type of PLGA, type and concentration of surfactants, power and duration of homogenization, and type of organic solvent and its ratio to the aqueous phase on the dependent physicochemical characteristics of the nanoparticles. The optimized nanoparticles were investigated using scanning electron microscope (SEM), Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Comparative evaluation of the drug release kinetics was carried out using different pH and different setups: flow cuvette (USP 4 apparatus) and Franz diffusion cuvette. In addition, the mucoadhesive properties and mycobacterial activity of PLGA-RIF NPs were studied.